Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate (ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) demonstrated some positive effects, but cross-resistances between ABI and ENZA that reduce activity have been suggested...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Doo Yong, Kang, Dong Hyuk, Kim, Jong Won, Kim, Do Kyung, Lee, Joo Yong, Hong, Chang Hee, Cho, Kang Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017207/
https://www.ncbi.nlm.nih.gov/pubmed/31861415
http://dx.doi.org/10.3390/cancers12010008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017207/
https://www.ncbi.nlm.nih.gov/pubmed/31861415
http://dx.doi.org/10.3390/cancers12010008

Ejemplares similares